Cardiovascular Research

Cardiovascular Research 2000 47(3):475-488; doi:10.1016/S0008-6363(00)00118-8
© 2000 by European Society of Cardiology

This Article Abstract FREE Full Text (PDF) Corrigendum (v57,p869) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Google Scholar Articles by Mezzetti, A. Articles by Cuccurullo, F. Search for Related Content PubMed PubMed Citation Articles by Mezzetti, A. Articles by Cuccurullo, F. Related Collections Related Article Social Bookmarking          What's this?

Copyright © 2000, European Society of Cardiology

Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm

Andrea Mezzetti^*, Francesco Cipollone and Franco Cuccurullo

Department of Medicine and Aging, University of Chieti "G D’Annunzio" School of Medicine, Chieti, Italy

^* Corresponding author. Centro per la Prevenzione dell’Aterosclerosi, la Diagnosi e Terapia dell’Ipertensione Arteriosa e delle Dislipidemie, Nuovo Policlinico SS. Annunziata, Via dei Vestini 66, 66013 Chieti, Italy. Tel.: +39-0871-3556-462; fax: +39-0871-3556-462 mezzetti{at}unich.it

Received 21 December 1999; accepted 26 April 2000

	Abstract

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
Long-term vascular complications still represent the main cause of morbidity and mortality in diabetic patients. Although randomized long-term clinical studies comparing the effects of conventional and intensive therapy have demonstrated a clear link between hyperglycemia and the development of complications of diabetes, they have not defined the mechanism through which excess glucose results in tissue damage. Evidence has accumulated indicating that oxidative stress may play a key role in the etiology of diabetic complications. Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential relevance to human vascular disease. Their formation in vivo seems to reflect primarily, if not exclusively, a nonenzymatic process of lipid peroxidation. Enhanced urinary excretion of 8-iso-PGF₂ has been described in association with both type 1 and type 2 diabetes mellitus, and correlates with impaired glycemic control. Besides providing a likely noninvasive index of lipid peroxidation in this setting, measurements of specific F₂ isoprostanes in urine may provide a sensitive biochemical end point for dose-finding studies of natural and synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF₂ in vitro suggest that it and other isoeicosanoids may modulate the functional consequences of lipid peroxidation in diabetes, evidence that this is likely in vivo remains inadequate at this time.

KEYWORDS Cholesterol; Coronary disease; Diabetes; Free radicals; Lipid metabolism

	1 Introduction

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
Diabetes mellitus is a major source of morbidity in developed countries and, among its comorbid conditions, atherosclerosis is perhaps the most important. Since the availability of insulin, up to three fourths of all deaths among diabetics can be directly attributed to coronary artery disease (CAD) [1]. In adult patients with diabetes, the risk of CAD is 3- to 5-fold greater than in nondiabetics despite controlling for other known CAD risk factors [1]. In patients with type 1 diabetes, up to one third will die of CAD by the age of 50 years [2]. A number of known risk factors for CAD, such as hypertension, central obesity, and dyslipidemia, are more common in diabetics than in the general population [1]. Despite this prevalence of risk factors, no more than 25% of the excess CAD risk in diabetes can be accounted for by known risk factors [2]. Thus diabetes represents a major contributing factor to the CAD burden in the developed world, and most of the excess attributed risk of CAD in diabetics cannot be readily quantified with the use of traditional risk factor analysis.

Diabetes is associated with a variety of metabolic abnormalities, principal among which are insulin resistance and hyperglycemia. Insulin resistance develops from obesity and physical inactivity, acting on a substrate of genetic susceptibility [3,4]. Insulin secretion declines with advancing age [5,6], and this decline may be accelerated by genetic factors [7,8]. Insulin resistance typically precedes the onset of type 2 diabetes and is commonly accompanied by other cardiovascular risk factors: dyslipidemia, hypertension, and prothrombotic factors [9,10]. There has been much debate as to whether or not hyperinsulinemia in subjects with type 2 diabetes may increase the coronary artery disease risk via potential adverse effects of insulin on the myocardium or coronary arteries due to growth stimulating effects or adverse effects on blood pressure, weight or lipids. In fact, CAD is often seen in subjects with newly diagnosed diabetes who could not have had a prolonged period of hyperglycemia [11]. However, in a feasibility study of intensive therapy with insulin compared with standard care in 153 men with type 2 diabetes on cardiovascular events, no differences in the rate of new events were detected between groups over a 2-year follow-up period [12]. Furthermore, the Diabetes Insulin-Glucose in Acute Myocardial Infarction (DIGAMI) study [13], with 620 diabetic subjects, showed that intensive insulin treatment was associated with a lower mortality rate than standard treatment in subjects with acute myocardial infarction (18.6% vs. 26.1%, P=0.03). The United Kingdom Prospective Diabetes Study [14] also showed that intensive treatment with insulin or oral sulphonylureas reduced the risk of myocardial infarction (15.8% vs. 18.1%, P=0.052), a reduction of borderline statistical significance. Insulin treatment did not increase the risk of cardiovascular disease. These studies suggest that the macrovascular complications of diabetes are more likely related to the degree of prevailing hyperglycemia or its associated cardiovascular risk factors and are not due to the administration of exogenous insulin.

The relation between hyperglycemia and CAD is the subject of considerable debate because serum glucose does not consistently predict the existence of CAD [2,15], especially in type 2 diabetes [15,16]. Presumably, this confusion stems from the reliance on a single blood glucose measurement, as recent prospective data have clearly established a link between a marker for chronic average glucose levels (HbA1_C) and cardiovascular morbidity and mortality [17]. There is considerable controversy with respect to the precise mechanism by which hyperglycemia may contribute to the development of CAD in diabetes. A number of equally tenable hypotheses have been suggested, including but not limited to, the Maillard, or advanced glycation end product (AGE) hypothesis [18,19], the aldose reductase hypothesis [20], oxidative stress [21–23], reductive stress (pseudohypoxia) [24,25], true hypoxia [26], carbonyl stress [27,28], altered lipoprotein metabolism [27,29,30], increased protein kinase C activity [31], and altered growth factor [32] or cytokine [33] activities. All of these hypotheses have strong proponents in academe, in medicine, and in the pharmaceutical industry. The list is long, perhaps because each hypothesis is a different reflection of an underlying common pathogenic mechanism, or perhaps because different tissues are sensitive to different mechanisms. The various hypotheses overlap and intersect with one another: AGE formation and altered polyol pathway activity may lead to oxidative stress, oxidative stress may accelerate AGE formation, reductive stress may lead to activation of protein kinase C, AGEs may induce oxidative stress and growth factor expression, and so on. The long list is a strong indication of the uncertainties in our understanding of the pathogenesis of diabetic complications.

In this article, we will present a current perspective on one of the above hypotheses, the oxidative stress hypothesis, and will discuss the rilevance of F₂-isoprostanes as new markers of in vivo oxidative stress.

	2 Oxidative stress in diabetes mellitus

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
Among the sequelae of hyperglycemia, excess oxidative stress has captured considerable attention as a potential mechanism for the increased vascular disease in diabetics. The established association between atherosclerosis and lipid peroxidation in plasma [34] and within the vascular wall [35] has led to a renewed interest in the oxidative stress of hyperglycemia as a potential mechanism for diabetic vascular disease. Early experimental evidence have supported the association between oxidative stress and hyperglycemia, showing that plasma from diabetic subjects contains increased levels of thiobarbituric acid-reactive substances [36] and lipid hydroperoxides [37], two classic markers of lipid peroxidation.

Consistent with the concept of enhanced lipid peroxidation in diabetes, Gopaul et al. [38] have reported that the average concentration of esterified 8-iso-PGF₂ (a major F₂-isoprostane) in plasma from 39 patients with type 2 diabetes was approximately threefold higher than in healthy individuals. Catella-Lawson et al. [39] have reported a trend toward increased urinary 8-iso-PGF₂ excretion in a group of 18 diabetics, with statistically significant elevations in patients presenting with diabetic ketoacidosis. Finally, in our recent study [40], urinary immunoreactive 8-iso-PGF₂ was significantly higher in a group of 62 type 2 and 23 type 1 patients than in age-matched control subjects by approximately twofold (Fig. 1).

View larger version (9K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 1 Urinary excretion rates of 8-iso-PGF2 in 62 patients with type 2 (upper panel) and 23 type 1 (lower panel) diabetes and matched healthy subjects. Dots represent individual measurements; horizontal bars represent mean value for each group (published by the permission of Davì et al., Circulation 1999;99:224–229).

 

	3 Putative mechanisms of oxidative stress in diabetes

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
The molecular mechanism of biological oxidation by glucose was first identified in 1912 and referred as the ‘Maillard reaction’ [41]. The Maillard reaction accounts for the glucose dependent, nonenzymatic covalent modification of proteins that accompanies hyperglycemic states. Initially, the Maillard reaction involves the combination of the aldehyde group of glucose in the open-chain form with amine groups on proteins to form a Schiff base followed by Amadori rearrangement to form fructoselysine. This reversible glycosylation of amino groups, or glycation, underlies the formation of HbA_1C, the well-recognized marker of chronic glycemic control in diabetes mellitus, and is not of any direct pathophysiological significance for the complications of diabetes. By contrast, the final stage of the Maillard reaction involves the irreversible oxidation, or glycoxidation, of fructoselysine to yield a host of advanced glycation end products (AGEs) such as W-(carboxymethyl)lysine, pentosidine, and pyrroline, the formation of which correlates directly with the vascular and renal complications of diabetes mellitus [42]. These carbohydrate-derived protein oxidation products are readily quantified with gas chromatography/mass spectroscopy and are more abundant in diabetics than in age-matched control subjects [42].

In addition to AGE formation by oxidation of fructoselysine, there are a number of other putative mechanisms that link hyperglycemia to oxidative stress. Among the most direct is the autoxidation of glucose. Monosaccharides with an -hydroxyaldehyde structure, like glucose, are subject to enediol rearrangement that results in the formation of an enediol radical ion [43]. The formation of this radical anion has two important implications. First, this species is capable of reduced molecular oxygen to form superoxide anion which, under certain circumstances, may contribute to the oxidation of lipids [44] or the activation of platelets [45]. Second, the dicarbonyl products formed by this pathway are quite reactive and may modify adjacent lysine groups to form AGEs such as N-(carboxymethyl)lysine directly. These reactions derived from glucose enolization are, however, dependent on transition metal ions [43], and the availability of free, redox-active transition metal ions in vivo is controversial. Recent data demonstrating glycation-induced ceruloplasmin fragmentation and free copper release offer one possible mechanism for a source of extracellular transition metals [46]. As an alternative mechanism of AGE-mediated oxidative stress, AGEs have also been shown to induce cellular lipid peroxidation through interacting with their specific surface receptor (RAGE) [47], and this effect can be attenuated by vitamin E [48]. Regardless of the mechanism for the synthesis of AGEs, several features of AGE action can have direct influence on the progression of atherosclerosis. In fact, in addition to their role in lipid peroxidation, AGEs enhance the aggregation of human platelets ex vivo [49]. Moreover, AGE-modified albumin has also been shown to induce monocyte tissue factor expression and procoagulant activity [50]. Thus, AGE formation on proteins and lipids appears to contribute to both lipid peroxidation and platelet activation and may therefore contribute to the rapid progression of CAD in diabetic patients.

One interesting point raised by several studies is the enzyme(s) responsible for free radical production in arterial vessel. NADH oxidase has been proposed to be a major source of superoxide anion (O₂^–) in normal and diseased blood vessels [51]. To test this hypothesis, Lund et al. [52] assessed O₂^– production in vessels from normal or diabetic rabbits that were stimulated by NADH oxidase. Superoxide production in response to NADH was >2-fold greater in carotid arteries from diabetic rabbits than in normal carotids. These data suggest increased propensity to generate O₂^– levels in arterial vessels from diabetic animals during treatment with NADH. Because numerous studies suggest that the mechanism of impaired endothelium-dependent relaxation in diabetes may involve inactivation of nitric oxide (NO) by oxygen-derived free radicals [53,54], increased activity of NAD/NADH oxidase in diabetic vessel could play a pivotal role in the early stage of vascular complications in diabetes.

In tissues where glucose uptake is independent of insulin, including retina, lens, kidney, and peripheral nerves, all tissue sites of diabetic complications, exposure to elevated glucose levels causes an increase in intracellular sorbitol and fructose levels due to increased activity of aldose reductase (AR) and sorbitol dehydrogenase (SDH) [55]. These two enzymes constitute the polyol pathway. Increased substrate flux through the polyol pathway not only increases cellular levels of sorbitol and fructose but also decreases the ratio of NADPH to NADP⁺ and increases the cytosolic NADH-to-NAD⁺ ratio [56].

The depletion of NADPH cell stores by AR may inhibit the activity of other NADPH-requiring enzymes. This possibility is supported by the finding that human umbilical vein endothelial cells exposed to 33 mmol/l glucose show a 42% decrease in NADPH concentration and a 34% reduction of glutathione release into the medium [57]. Moreover, the same endothelial cells cultured under conditions of high glucose and oxidative stress (200 µmol/l H₂O₂) reduce the supply of NADPH to various NADPH-dependent pathways, including the reduced glutathione redox cycle [58]. Decreased levels of reduced glutathione increase both the susceptibility of endothelial cells to damage by H₂O₂ [57] and the cytotoxicity by a xenobiotic (1-chloro-2,4-dinitrobenzene) in K502 cells that possess characteristics for erythroid cells [59]. On the other hand, there is no direct proof that tissue levels of NADPH are depleted in vivo in diabetes.

The hyperglycemia-induced increase in the NADH-to-NAD⁺ ratio is referred to as hyperglycemic pseudohypoxia [56] and is thought to play a role in diabetic complications. Part of this idea is based on similarities existing between the metabolic consequences of pseudohypoxia (raised NADH-to-NAD⁺ ratio) and true hypoxia. Impaired blood flow leading to ischemia has been noted in tissues exposed to diabetic complications, such as nerve, which may explain the benefit of hyperbaric oxygen [60]. Both true hypoxia and pseudohypoxia may generate free radicals: the latter via an increased synthesis of prostaglandin H₂ from prostaglandin G₂ as the enzyme hydroperoxidase uses NADH as cofactor [61], the former via ischemia/reperfusion injury [62]. A vicious cycle might be envisaged in which free radicals are both cause and consequence, at least in part, of ischemia.

Because of mutual facilitatory interactions between the main mediators of hyperglycemic damage to tissues (polyol pathway, oxidative stress, AGEs, prostanoid metabolism), it is not surprising that correction of any of them may result in amelioration of endothelium-dependent vasodilatation. In experimental diabetic neuropathy, for example, aminoguanidine, inhibitors of AR, and antioxidants are all effective in ameliorating or preventing early neurovascular dysfunction [63].

	4 Isoprostanes as new markers of in vivo lipid peroxidation

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
Unlike the quantitation of AGEs and AGE-modified proteins, the quantitation of lipid peroxidation in the setting of hyperglycemia has been more problematic. Recently F₂ isoprostanes, a novel class of prostanoid-like compounds has been described by Morrow and Roberts [64]. F₂ isoprostanes are a family of Prostaglandin (PG) F₂ isomers (Fig. 2) first described as products of noncyclooxygenase oxidative modifications of arachidonic acid that have resulted from free-radical attack of cell membrane phospholipids [65] or circulating LDLs [66]. In contrast to classic prostaglandins, which are formed through the action of PGH synthase isozymes from free arachidonic acid [67], F₂ isoprostanes are formed in situ from the fatty acid backbone esterified in membrane phospholipids. Isoprostanes maybe formed by either of two routes of peroxidation [68,69], an endoperoxide mechanism (Fig. 2, upper panel) or a dioxetane/endoperoxide mechanism (Fig. 2, lower panel). In the former, the first oxygen molecule is incorporated into the endoperoxide ring to form the two hydroxyl groups on the PGF ring. In the latter, by contrast, it is the second oxygen molecule that is incorporated into the PGF ring. Also 5- and 15-hydroperoxy radicals can only form Groups VI and III by the dioxetane/endoperoxide mechanism. The radical at position 10 of arachidonic acid, by contrast, can yield isoprostanes by both mechanisms. Thus, hydroperoxy radicals formed at 8 and 12 have the option to proceed to form a dioxetane ring (Fig. 2, upper panel) or a dioxypentane ring (Fig. 2, lower panel) on a competitive basis, although it is not yet clear which is favored. Recent attention has focused upon Group VI isoprostanes. These compounds may be derived from a 9-hydroperoxy radical by the endoperoxide mechanism or from a 5-hydroperoxy radical by the dioxetane/endoperoxide mechanism. However, both are derived from an initial hydrogen atom abstraction at position 7 of arachidonic acid. Abstraction at carbon 13 can give rise to 11- and 15-hydroperoxy radicals, yielding only one series (Group III) of isoprostanes. A radical at position 10 of arachidonic acid gives a radical at 8 and 12, which yields groups V and IV, respectively. If the dioxetane mechanism is operative, the same 8- and 12-hydroperoxy radicals will yield Groups IV and V, respectively. After their formation, isoprostanes are released from the membrane phospholipids in response to cellular activation, presumably through a phospholipase-mediated mechanism; they circulate in plasma and are excreted in the urine [70,71]. They may circulate as the free form or as esters in phospholipids in plasma. The factors that regulate release of endogenous isoprostanes from cell membranes and interconversion between the free and esterified forms are presently poorly understood. It is conjecturable that hyperglycemia could influence the release of isoprostanes from cell membranes via increased activation of protein kinase C and phospholipase A₂.

View larger version (16K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 2 Formation of four types of isoprostanes by the two routes of peroxidation, an endoperoxide (upper panel) or dioxetane/endoperoxide (lower panel) mechanism (modified from Lawson JA. et al., J Biol Chem 1999;274:24441–24444).

 
Given the ubiquitous distribution of the precursor arachidonic acid, isoprostane biosynthesis can occur in virtually all of the cellular players of the atherosclerotic lesion, including monocytes [72]. Indeed, coincubation of activated human monocytes with LDL resulted in a time-dependent formation of the F₂ isoprostane 8-iso-prostaglandin (PG) F₂ (also referred to as iPF₂-III [73]), but not of PGE₂ or thromboxane (TX) B₂, coincident with LDL oxidation [72]. The increase in 8-iso-PGF₂ formation was associated with an increase in thiobarbituric acid-reactive substance (TBARS) and hydroperoxide levels. This phenomenon was prevented by the oxygen free-radical scavengers superoxide dismutase (SOD) and butylhydroxytoluene (BHT) but not by cyclooxygenase inhibitors [72]. Consistent with these in vitro studies, immunolocalization of 8-iso-PGF₂ in the monocytes/macrophages and vascular smooth muscle cells of human atherosclerotic tissue has recently been described in specimens obtained during carotid endarterectomy [74].

In addition to a cyclooxygenase-independent mechanism of formation involving peroxidative attack on arachidonic acid, in which bicyclic endoperoxide intermediates are formed that are then reduced to give rise to isoprostanes such as 8-iso-PGF₂, there is recent evidence that 8-iso-PGF₂, unlike other F₂ isoprostanes, can be produced as a minor product of the cyclooxygenase activity of platelet PGH synthase-1 in response to platelet stimulation with collagen, thrombin, or arachidonate [71,75]. Activated platelets can generate 8-iso-PGF₂ and TXB₂ in a molar ratio of 1:1000 [71,75]. A second enzyme endowed with cyclooxygenase activity, PGH synthase-2, can be expressed in different cell types in response to inflammatory and mitogenic stimuli (reviewed in Reference [67]). Induction of PGH synthase-2 in human monocytes by concanavalin A, phorbol ester, or bacterial lipopolysaccharide was associated with cyclooxygenase-dependent formation of 8-iso-PGF₂ and PGE₂ in a molar ratio ranging from 1:5 to 1:30 [72,76]. Dexamethasone, an inhibitor of PGH synthase-2 induction, and L-745337, a selective inhibitor of the cyclooxygenase activity of monocyte PGH synthase-2 [77], dose-dependently suppressed 8-iso-PGF₂ and PGE₂ formation with similar potency [72,76]. However, the contribution of cyclooxygenase-dependent mechanisms to the formation of 8-iso-PGF₂ in vivo appears to be negligible [71], and the general assumption that measurements of this F₂-isoprostane in plasma or urine are a reflection of nonenzymatic lipid peroxidation has been validated in clinical settings of platelet and/or monocyte activation (see below).

	5 Biological effects of isoprostanes

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
Several isoprostanes are known to have biological effects in vitro via membrane receptors for prostaglandins. Their formation in lipid bilayers by a free radical-catalyzed mechanism may contribute importantly to alterations in the fluidity and integrity of cellular membranes. In addition, 8-iso-PGF₂ is a potent vasoconstrictor [78] and induces DNA synthesis in vascular smooth muscle cells, through interaction with TXA₂ receptor [79] or perhaps with specific receptors [80]. Similarly, another F₂ isoprostane 12-epi-PGF₂, activates PGF₂ receptors and stimulates proliferative responses in fibroblasts [81].

Formation of isoprostanes in situ in the phospholipid bilayer may modify cellular function. Subsequent cleavage may release products, such as 8-iso-PGF₂, that modify aspects of platelet function such as adhesive reactions and activation by low concentrations of other agonists. Formation of isoprostanes in monocytes may modify aspects of their function, such as expression of tissue factor [82]. Similarly, formation of isoprostanes in oxidized LDL may result in their uptake by macrophages, resulting in the formation of foam cells. Isoprostanes may also modify vascular smooth muscle cell function and accumulate in these cells in proximity to atherosclerotic plaques (Fig. 3).

View larger version (21K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 3 Potential sites of isoprostane formation and cellular targets of 8-iso-PGF2 of relevance to atherothrombosis. ELAM indicates endothelial leukocyte adhesion molecule; PGI2, prostacyclin; PAF, platelet-activating factor; TX, thromboxane; and VCAM, vascular cell adhesion molecule (published by the permission of Patrono et al., Arterioscler Thromb Vasc Biol 1997;17:2309–2315).

 
Concentration of 8-iso-PGF₂ in the range of 1 nmol/l to 1 µmol/l induces a dose-dependent increase in platelet shape change, calcium release from intracellular stores, and inositol phosphates [80,83]. Moreover, 8-iso-PGF₂ causes dose-dependent, irreversible platelet aggregation in the presence of concentrations of collagen, ADP, arachidonic acid, and PGH₂/TXA₂ analogues that, when acting alone, fail to aggregate platelets [80]. These effects are prevented by PGH₂/TXA₂ receptor antagonists and 8-iso-PGF₂ may cross-desensitize biochemical and functional responses to thromboxane mimetics [84,85]. Moreover, recent evidences based on genetically modified mice have confirmed that the effects of bioactive isoprostanes 8-iso-PGF₂ and iPE₂-III on vascular tone and platelet function are transduced via activation of the thromboxane A₂ receptor in vivo in the mouse and do not depend on the existence of related, but distinct isoprostane receptors [86]. Thus, although 8-iso-PGF₂ fails to activate either of the TX receptor isoforms described in platelet at concentrations that typically circulate during syndromes of oxidant stress [80], evidences suggesting a distinct receptor for this molecule are inconclusive. Furthermore, although isoprostanes may act as incidental ligands for prostanoid receptors, their effects may differ from the cognate ligand. For example, 8,12-iso-iPF₂-III, which ligates the PGF₂ receptor and causes a hypertrophic response in cardiomyocytes, activates distinct as well as overlapping downstream signaling pathways when compared with PGF₂ [87].

Whether the local concentrations of isoprostanes achieved in vivo are sufficient to allow them to act as a ligand for prostanoid receptors remains unclear. However, the ability of 8-iso-PGF₂ to amplify the aggregation response to subthreshold concentrations of platelet agonists might be relevant to setting, such as diabetes mellitus, where persistent platelet activation and enhanced free-radical formation coincide. In fact, diabetes is characterized by platelet activation in vivo, as reflected by enhanced thromboxane metabolite excretion [88]. Immunoreactive 8-iso-PGF₂ is altered in patients with diabetes and appears to contribute to platelet activation in this setting [40]. Paired urinary measurements of 8-iso-PGF₂ and 11-dehydro-TXB₂ (a major metabolite of TXA₂) in diabetic patients revealed a highly significant linear correlation between the two. Urinary immunoreactive 8-iso-PGF₂ was unchanged following a 2-week dosing with aspirin or indobufen, a reversible cyclooxygenase inhibitor, despite complete suppression of thromboxane metabolite excretion, indicating that the oxidative stress in diabetics is likely to be a cause and not a consequence of platelet activation [40]. Consistent with the hypothesis of enhanced 8-iso-PGF₂ formation's contribution to platelet activation in this setting, dose-dependent suppression of the former by vitamin E supplementation was associated with comparable reductions in 11-dehydro-TXB₂ excretion. Thus, enhanced nonenzymatic peroxidation of arachidonic acid may provide a biochemical link between oxidant stress and platelet activation in the setting of diabetes mellitus.

The studies of 8-iso-PGF₂ formation conducted so far appear to exclude a significant contribution from a cyclooxygenase-dependent mechanism of biosynthesis in vivo. This is particularly supported by no effects of aspirin and other nonspecific cyclooxygenase inhibitors on urinary 8-iso-PGF₂ in diabetic patients. The availability of selective inhibitors of PGH synthase-2 will permit further definition of the potential contribution of this pathway to formation of 8-iso-PGF₂, particularly in the setting of complicated diabetes, were induction of this enzyme might be anticipated.

	6 Hyperglycemia and isoprostane generation

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
It is debated if hyperglycemia per se is causally related to cardiovascular disease or is merely a marker for some underlying factor that causes both diabetes and CAD. While there is a definite association between the level of glycemia both above and below the threshold for diabetes and cardiovascular risk, proof that hyperglygemia causes CAD was for long time less convincing. Establishing a causal link between hyperglycemia and CAD is likely to be difficult given that both are complex conditions. Recently, it has been provided an important first step in understanding the implications of hyperglycemia-induced lipid peroxidation and increased production of 8-iso-PGF₂ in diabetic vascular disease [40]. Using a specific radioimmunoassay, it has been found that urinary excretion of 8-iso-PGF₂ in diabetic patients was essentially twice that of healthy age-matched control subjects (Fig. 1). With regard to urinary 8-iso-PGF₂ excretion, similar findings were observed both for type 2 and type 1 diabetic patients [40] (Fig. 1). These concordant observations between type 2 and type 1 diabetic patients would tend to implicate hyperglycemia as the culprit metabolic derangement, since this is a major common feature of both patient populations. Consistent with this notion, we have reported that improved metabolic control of type 2 diabetic patients significantly reduced urinary 8-iso-PGF₂ levels by 32% [40] (Fig. 4). Furthermore, reports that improved glycemic control by pancreatic islet transplantation reduces vascular oxidative stress and reverses antioxidant enzyme upregulation in rats with streptozotocin-induced diabetes are consistent with hyperglycemia as a source of oxidative stress [89]. This increase in 8-iso-PGF₂ was significantly correlated with blood glucose and increased platelet activation. On the basis of prior studies indicating that 8-iso-PGF₂ amplifies agonist-induced platelet aggregation [80], these results strongly suggest that increased lipid peroxidation in diabetic patients leads to the formation of 8-iso-PGF₂, which, in turn, leads to platelet activation. In support of this hypothesis, the reduction of 8-epi-PGF₂ formation through improved metabolic control also reduced platelet activation [40]. Taken together, these data suggest that the extent of metabolic control has a profound influence on the degree of oxidative stress and platelet activation in patients with diabetes.

View larger version (19K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 4 Changes in F2-isoprostane formation associated with improved metabolic control in type 2 diabetes. Individual measurements of 8-iso-PGF2 excretion are represented for 17 patients who achieved improved metabolic control (ie, blood glucose<200 mg/dL and HbA1c<9%) after intensive monitoring and treatment (published by the permission of Davì et al., Circulation 1999;99:224–229).

 
Whether F₂-isoprostanes can also influence insulin resistance in diabetic patients is presently poorly understood. Recently, Laight et al. [90] have investigated oxidant stress, glucose tolerance and glucose-stimulated insulin responses in the obese Zucker rat, a widely used model of insulin resistance. The plasma level of 8-iso-PGF₂ was elevated approximately 5-fold in old obese relative to age-matched, insulin-sensitive. Supplementation of the diet with vitamin E reduced plasma 8-iso-PGF₂ and concomitantly reversed glucose-stimulated hyperinsulinemia in this experimental model. This could explain, at least in part, the beneficial effects of antioxidants on insulin action previously reported in literature [91]. However, whether 8-iso-PGF₂ plays a pivotal role also in patients with hyperinsulinemia and insulin resistance but without overt hyperglycemia is still unclear at this time.

	7 Potential role of isoprostanes in atherosclerosis

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
Given the abundant information that oxidation of LDL confers properties thought relevant to atherogenesis [92], there has been interest in the potential of isoprostane measurements both to identify patient populations for interventional studies and for dose selection for antioxidants employed in such clinical trials [93].

A limited number of studies have been completed during the past 5 years addressing the formation of F₂ isoprostanes in clinical settings putatively associated with oxidative damage, often as a result of long-standing metabolic abnormalities.

Persistently enhanced formation of F₂-isoprostanes has been reported in association with several clinical conditions, including diabetes mellitus [38–40], hypercholesterolemia [94,95], coronary ischemia-reperfusion syndromes [96,97], unstable angina [98], chronic obstructive pulmonary disease [99], cystic fibrosis [100] and cigarette smoking [101,102], conditions putatively characterized by increased lipid peroxidation in response to the complex metabolic abnormalities or various constituents of cigarette smoke. Accelerated LDL oxidation [103] as well as platelet activation [104], are common features of these conditions.

Although diabetes mellitus is a clearly established risk factor for cardiovascular disease, the mechanism(s) responsible for accelerated atherogenesis remain elusive. Altered lipoprotein levels; changes in lipoprotein composition, possibly affecting LDL binding to its receptors; and reduced LDL clearance resulting from impaired receptor recognition of glycated LDL have been described in diabetic patients (reviewed in Reference [105]). Moreover, both high glucose levels and protein glycation enhance LDL oxidation by metal ions, and these reactions also yield advanced glycosilation end (AGE) products [103,105]. In fact, LDLs isolated from type 2 diabetics contain higher levels of AGE products and conjugated dienes and are more easily oxidized by copper than native LDL [106]. In addition, plasma from patients whose type 1 diabetes mellitus is poorly controlled has less antioxidant capacity [107]. Oxidatively modified LDL has been found in foam cells and atherosclerotic plaques and has been shown to acquire a variety of properties possibly relevant to the process of atherogenesis [35,108].

When LDL is oxidized in vitro, either by exposure to copper or by coincubation with endothelial cells, isoprostanes are formed in a time-dependent manner, along with more conventional indices of lipid peroxidation [66,109,110]. However, it is unknown how oxidizability of LDL, either in vitro or ex vivo, relates to actual LDL oxidation in vivo. Isoprostanes are present in human atherosclerotic plaque [74,111], as are isoeicosatrienoic acids, which appear to be even more abundant [112]. Formation of isoprostanes in monocytes/macrophages in atherosclerotic plaques may modify aspects of their function, such as expression of tissue factor [82]. Moreover, formation of isoprostanes in oxidized LDL results in their uptake by monocytes/macrophages, resulting in the formation of foam cells. Finally, isoprostanes may also accumulate in vascular smooth muscle cell in atherosclerotic plaques (Fig. 3). Thus, although a functional role for isoprostanes in atherogenesis remains to be established, discriminant production of isoprostanes by both reactive oxygen species and monocyte PGH synthase 2 within atherosclerotic plaques renders it a candidate molecule to transduce, at least in part, the effects of lipid peroxidation and inflammation on vascular dysfunction.

To address this hypothesis, Praticò et al. [113] have recently studied isoprostane generation before and after vitamin E supplementation in the hypercholesterolemic, ApoE-deficient mouse that develops atherosclerosis-type lesions on a chow diet. Supplementation with vitamin E significantly reduced isoprostane generation, but had not effect on plasma cholesterol levels in apoE knock-out mice. This intervention also suppressed the elevated levels of iPF₂-VI esterified in LDL and in vascular tissue and retarded the development of atherosclerosis, despite persistent hypercholesterolemia [113].

Despite these observations, it is difficult to relate the concentrations of isoprostanes used to evoke biological effects in vitro to what might pertain in vivo. First, a myriad of products is formed under conditions of oxidant stress, and yet, to date, studies have concentrated on single isomers. Second, these compounds may be subject to rapid reesterification after release from membrane phospholipids. Finally, the mechanisms and regulation of their release are poorly understood. Nonetheless, there are hints that they might have some relevance in vivo. A thromboxane receptor antagonist is more effective at preventing platelet-dependent coronary occlusion in dogs after thrombolysis than aspirin, despite complete inhibition of thromboxane formation by the latter [114]. This observation suggests activation of the thromboxane receptor by a ligand distinct from TXA₂ and 8-iso-PGF₂ is known to increase during coronary reperfusion in this model [96]. Moreover, in patients with unstable angina, roughly 50% of the individual variation in aspirin-insensitive TXA₂ biosynthesis could be accounted for by the individual variation in 8-iso-PGF₂ formation [98]. Finally, vitamin E suppresses not only 8-iso-PGF₂ in patients with diabetes but also the elevated levels of a thromboxane metabolite [40]. Perhaps, as suggested above, platelet active isoprostanes, such as 8-iso-PGF₂, contribute to the enhanced platelet activation in diabetic patients at risk of cardiovascular events.

	8 Effects of antioxidants

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
Numerous epidemiological studies have shown that dietary intake of vitamin E is inversely associated with the risk of cardiovascular disease, though randomized intervention trials have uncertain proved the cardiovascular benefit from vitamin treatment [115]. In general, the epidemiological studies have been interpreted to suggest that prevention of cardiovascular disease requires large amounts of vitamin E, in excess of the conventional dietary intake. However, there is substantial uncertainty as to the optimal dose of vitamin E supplementation, largely because of inadequate biological end points for its efficacy. This is reflected in a wide range of vitamin E doses tested in randomized clinical trials, from as low as 50 mg daily to as high as 500 mg daily [115–117], and in a broad spectrum of clinical benefits, from a 60% reduction in nonfatal myocardial infarction in the CHAOS study [116] to the absence of benefits in the recent HOPE trial [117]. A number of mechanisms have been suggested to contribute to the putative beneficial effects of vitamin E, including inhibition of LDL oxidation and prevention of fatty streak formation, stabilization of coronary lesions, a direct antiplatelet effect, or improvement of endothelium-dependent vasodilatation.

Limited information is available on the effects of vitamin E on F₂ isoprostane formation. Thus, Reilly et al. [102] have reported no significant changes in urinary 8-iso-PGF₂ excretion following a 5-day course of vitamin E supplementation in a limited number of moderate (100 U/d) or heavy (800 U/d) smokers. In contrast, vitamin C (2 g/d) alone or in combination with vitamin E significantly depressed urinary 8-iso-PGF₂ in heavy smokers to a comparable level achieved by smoking cessation [102]. Similarly, we found that supplementation with vitamin E up to 1200 mg did not significantly affect the urinary excretion of 8-iso-PGF₂ in chronic smokers [118]. In contrast, two-week dosing with vitamin E (100 to 600 mg daily) was found to reduce immunoreactive 8-iso-PGF₂ excretion in a dose-dependent fashion in type 2 diabetic subjects, with all measurements failing within the range of healthy subjects at 600 mg daily [40].

Failure of vitamin E supplementation to reduce thromboxane metabolite excretion in healthy cigarette smokers [118] provides important support to the contention [40,94] that vitamin E may blunt F₂-isoprostane-mediated amplification of platelet activation in several pathological clinical setting, such as those depicted in Fig. 5, rather than exerting a direct antiplatelet effect.

View larger version (14K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 5 (Panel A) Changes in plasma vitamin E levels and urinary excretion of 8-iso-PGF2 excretion associated with vitamin E supplementation (600 mg/day for 2 weeks) in patients type 2 diabetes mellitus (NIDDM: Ref. [40]), hypercholesterolemia (HC: Ref. [94]), cystic fibrosis (Ref. [100]) and in healthy cigarette smokers (Ref. [118]). Each solid line connects mean (±S.E.M.) values measured before and after vitamin E supplementation. (Panel B) The slope of these lines is linearly correlated with the mean basal rate of 8-iso-PGF2 excretion in each clinical setting (r=0.976, P=0.023) (published by the permission of Patrignani et al., Circulation, in press).

 
The overall picture emerging from a series of studies of vitamin E supplementation using the in vivo formation of F₂ isoprostane as the primary biochemical end-point [40,94,102,113,118] suggests that the effect of vitamin E on lipid peroxidation can not be equated to that of a conventional drug blocking an enzyme or receptor in a reproducible fashion in the vast majority of patients exposed to treatment. Most likely, both the mechanism(s) responsible for enhanced oxidant stress and the rate of lipid peroxidation are important determinants of the antioxidant effects of vitamin E supplementation. This hypothesis may help interpreting the conflicting and largely disappointing results of recently completed trials of vitamin E supplementation in patients with ischemic heart disease [116,117,119]. Any protective effect of antioxidant intervention, that is readily apparent in the setting of genetically determined enhanced lipid peroxidation [113], is likely to be diluted by inclusion of a large proportion of patients with low levels of lipid peroxidation because of dietary habits (such as in the GISSI-Prevenzione Study carried out in the setting of a largely Mediterranean diet: Ref. [119]) or lack of metabolic abnormalities associated with oxidant stress.

Thus, F₂ isoprostanes may have practical implications for the use of vitamin E supplements for cardiovascular prevention in diabetic patients, and may help to resolve some of the uncertainty about the optimal dose of vitamin E supplementation. Moreover, present evidences suggest the need to re-evaluate the response of potential target populations based on non-invasive measurements of F₂ isoprostane formation as a rationale basis for new large-scale interventional trial design.

	9 Conclusion and summary

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 
Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential relevance to diabetes and cardiovascular diseases. Their formation seems to reflect primarily, if not exclusively, a nonenzymatic process of lipid peroxidation in vivo. Enhanced urinary excretion of 8-iso-PGF₂ has been repeatedly characterized in association with diabetes mellitus. Besides providing a reliable, noninvasive index of lipid peroxidation in this setting, measurements of specific F₂ isoprostanes, such 8-iso-PGF₂, in urine may provide sensitive biochemical end-points for dose-findings studies of natural and synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF₂ in vitro suggest that it and other isoeicosanoids [120,121] may modulate the functional consequences of lipid peroxidation in diabetes, evidences that this is likely in vivo are growing but are not yet conclusive at this time.

Time for primary review 29 days.

	Acknowledgements

 
We are indebted to Dr. Carlo Patrono for helpful suggestions in the preparation of the manuscript.

	References

Top Abstract 1 Introduction 2 Oxidative stress in... 3 Putative mechanisms of... 4 Isoprostanes as new... 5 Biological effects of... 6 Hyperglycemia and isoprostane... 7 Potential role of... 8 Effects of antioxidants 9 Conclusion and summary References

 

1. Bierman E.L. George Lyman Duff Memorial Lecture: Atherogenesis in diabetes. Arterioscler. Thromb. (1992) 12:647–656.[Free Full Text]
2. Pyorala K., Laasko M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev. (1987) 3:463–524.[Medline]
3. Gerick J.E. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr. Rev. (1998) 19:491–503.[Abstract/Free Full Text]
4. Chisholm D.J., Camphell L.V., Kraegen E.W. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin. Exp. Pharmacol. Physiol. (1997) 24:782–784.[ISI][Medline]
5. Muller D.C., Elahi D., Tobin J.D., Andres R. The effect of age on insulin resistance and secretion: a review. Semin. Nephrol. (1996) 16:289–298.[ISI][Medline]
6. Dechenes C.J., Verchere C.B., Andrikopoulos S., Kahn S.E. Human aging is associated with parallel reductions in insulin and amylin release. Am. J. Physiol. (1998) 275:E785–E791.[ISI][Medline]
7. Pimenta W., Korytkowski M., Mitrakou A., Jenssen T., Yki-Jarvinen H., Evron W., Dailey G., Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. J Am Med Assoc (1995) 273:1855–1861.[Abstract]
8. Humphriss D.B., Stewart M.W., Berrish T.S., Barriocanal L.A., Trajano L.R., Ashworth L.A., Brown M.D., Miller M., Avery P.J., Alberti K.G., Walker M. Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia (1997) 40:1185–1190.[CrossRef][ISI][Medline]
9. Hopkins P.N., Hunt S.C., Wu L.L., Williams G.H., Williams R.R. Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? Curr. Opin. Lipidol. (1996) 7:241–253.[ISI][Medline]
10. Gray R.S., Fabsitz R.R., Cowan L.D., Lee E.T., Howard B.V., Savage P.J. Risk factor clustering in the insulin resistance syndrome: the Strong Heart Study. Am. J. Epidemiol. (1998) 148:869–878.[Abstract/Free Full Text]
11. Fontbonne A., Charles M.A., Thibult M., Richard J.L., Claude J.R., Warnet J.M., Rosselin G.E., Eschwege E. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia (1991) 34:356–361.[CrossRef][ISI][Medline]
12. Abraira C., Colwell J., Nuttall F., et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch. Intern. Med. (1997) 157:181–188.[Abstract]
13. Malmberg K., Ryden L., Suad E., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J. Am. Coll. Cardiol. (1995) 26:57–65.[Abstract]
14. Prospective Diabetes Study Group U.K. Intensive blood glucose control with suophonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.[CrossRef][ISI][Medline]
15. Nathan D.M. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann. Intern. Med. (1996) 124:86–89.[Abstract/Free Full Text]
16. Moss S.E., Klein R., Klein B.E., Meuer S.M. The association of glycemia and cause-specific mortality in a diabetic population. Arch. Intern. Med. (1994) 154:2473–2479.[Abstract]
17. Singer D.E., Nathan D.M., Anderson K.M., Wilson P.W.F., Evans J.C. Association of HbA_1C with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes (1991) 41:202–209.[CrossRef][ISI]
18. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann. Rev. Med. (1996) 46:223–234.[CrossRef][ISI]
19. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes (1997) 46(Suppl. 2):S19–S25.[CrossRef][ISI][Medline]
20. Hotta N. New approaches for treatment in diabetes: aldose reduclase inhibitors. Biomed. Pharmacother. (1995) 49:232–243.[CrossRef][Medline]
21. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes (1991) 40:405–412.[CrossRef][ISI][Medline]
22. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care (1996) 19:257–267.[Abstract]
23. Van Dam P.S., Van Asbeck B.S., Erkelens B.W., Marx J.J.M., Gispen W.-H., Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab. Rev. (1995) 11:181–192.[ISI][Medline]
24. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., van den Enden M., Kilo C., Tilton R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes (1993) 42:801–813.[CrossRef][ISI][Medline]
25. Ido Y., Kilo C., Williamson J.R. Cytosolic NADH/NAD*, free radicals, and vascular dysfunction in early diabetes mellitus. Diabetologia (1997) 40(Suppl. 2):S115–S117.[CrossRef][ISI][Medline]
26. Cameron N.E., Cotter M.A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes (1997) 46(Suppl. 2):S31–S37.[ISI][Medline]
27. Lyons T.J., Jenkins A.J. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev. (1997) 5:365–391.
28. Degenhardt T.P., Brinkmann-Frye E., Thorpe S.R., Baynes J.W. The maillard reaction in food and medicine. O’Brien J., Nursten H.E., Crabbe M.J.C., Ames J.M., eds. (1998) London: Royal Society of Chemistry. 3–10.
29. Witztum J.L. Role of modified lipoproteins in diabetic macroangiopathy. Diabetes (1997) 46(Suppl. 2):S112–S114.[ISI][Medline]
30. Lopes-Virella M.F., Mironova M., Virella G. LDL-containing immune complexes and atherosclerosis in diabetes. Diabetes Rev. (1997) 5:410–424.
31. Ishii H., Daisuke K., King G.L. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J. Mol. Med. (1998) 76:21–31.[CrossRef][ISI][Medline]
32. Pfeiffer A., Schatz H. Diabetic microvascular complications and growth factors. Exp. Clin. Endocrinol. Diabetes (1995) 103:7–14.[ISI][Medline]
33. Sharma K., Ziyadeh F.N. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Sem. Nephrol. (1997) 17:80–92.[ISI][Medline]
34. Mezzetti A., Guglielmi M.D., Pierdomenico S.D., Costantini F., Cipollone F., De Cesare D., Bucciarelli T., Ucchino S., Chiarelli F., Cuccurullo F., Romano F. Increased systemic oxidative stress after elective endarterectomy. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2659–2665.[Abstract/Free Full Text]
35. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. (1991) 88:1785–1792.[ISI][Medline]
36. Nishigaki I., Hagihara M., Tsunekawa H., Maseki M., Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem. Med. (1981) 25:373–378.[CrossRef][ISI][Medline]
37. Nourooz-Zadeh J., Tajaddini-Sarmadi J., McCarthy S., Betteridge D.J., Wolff S.P. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes (1995) 44:1054–1058.[CrossRef][ISI][Medline]
38. Gopaul N.K., Anggard E.E., Mallet A.I., Betteridge D.J., Wolff S.P., Nourooz-Zadeh J. Plasma 8-epi-PGF₂ levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. (1995) 368:225–229.[CrossRef][ISI][Medline]
39. Catella-Lawson F., Kapoor S., Praticò D., Braunstein S.N., Caraballo V., FitzGerald G.A. Oxidative stress and diabetes mellitus. J. Invest. Med. (1996) 44:223A. Abstract.
40. Davì G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., Pennese E., Vitacolonna E., Bucciarelli T., Costantini F., Capani F., Patrono C. In vivo formation of 8-iso-prostaglandin F₂ and platelet activation in diabetes mellitus. Effects of improved metabolic control. Circulation (1999) 99:224–229.[Abstract/Free Full Text]
41. Maillard L.C. Action des adices amines sur les sucres: formation des melanoidines par voie methodique. C.R. Hebd. Seances Acad. Sci. (1912) 154:66–68.
42. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., Lyons T.J. Maillard reaction products and their relation to the complications of diabetes. J. Clin. Invest. (1993) 91:2470–2478.[ISI][Medline]
43. Wolff S.P., Dean R.T. Glucose autoxidation and protein modification: their potential role of autoxidative glycosylation in diabetes. Biochem. J. (1987) 245:243–250.[ISI][Medline]
44. Keaney J.F. Jr., Frei B. Natural antioxidants in human health and disease. Frei B., ed. (1994) San Diego, CA: Academic Press. 303–352.
45. Salvemini D., de Nucci G., Sneddon J.M., Vane J.R. Superoxide anions enhance platelet adhesion and aggregation. Br. J. Pha